Researchers identify antibody that removes amyloid plaques without the risk of brain bleeds
As people age, a normal brain protein known as amyloid beta often starts to collect into harmful amyloid plaques in the brain. Such plaques can be the first step on the path to Alzheimer s dementia. When they form around blood vessels in the brain, a condition known as cerebral amyloid angiopathy, the plaques also raise the risk of strokes.
Several antibodies that target amyloid plaques have been studied as experimental treatments for Alzheimer s disease. Such antibodies also may have the potential to treat cerebral amyloid angiopathy, although they haven t yet been evaluated in clinical trials. But all of the anti-amyloid antibodies that have successfully reduced amyloid plaques in Alzheimer s clinical trials also can cause a worrisome side effect: an increased risk of brain swelling and bleeds.
Amyloid deposits in the brain increase the risk of dementia and strokes. Researchers at Washington University School of Medicine in St. Louis have identified an antibody that clears amyloid deposits from the brain without raising the risk of brain bleeds.